FDA grants fast track status to FELIQS’ FLQ-101 for ROP
FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.
Related Articles
Harrow announces expanded market access for cyclosporine ophthalmic solution in 2025 Medicare Part D Program
Harrow announced that starting in January 2025, Vevye will be covered under key Medicare Part D formularies and across major insurance programs, expanding access to…
Knowledge of Glaucoma Among New Patients to a Tertiary Eye… : Journal of Glaucoma
roughout the healthcare system. Purpose: To investigate the depth of knowledge about glaucoma among patients who were referred to a tertiary eye hospital for their…
HuidaGene Therapeutics’ IND application for HG202 for the treatment of nAMD cleared by FDA
The drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD).
AI Hopes
We speak with Elad Serfaty, Chief Executive Officer of OrCam Technologies, about assistive technology for patients with low vision
The Evil Magnet
Four cases in which IOLs behaved like magnets inside the eye by attracting deposits that might affect the patients’ vision.
Shifting Paradigms in Glaucoma Therapy: Advances in Medications, Lasers, and Surgery
This course reviews growing clinical data and real-world evidence that support a variety of initial treatments for glaucoma, including sustained release medi
Visual Quality, Patient Satisfaction, and Photic Phenomena With a Diffractive Intraocular Lens and Its New Evolved Materials Version | Journal of Refractive Surgery
Purpose To assess the visual quality, patient satisfaction, and photic phenomena 3 and 12 months after the implantation of two similar diffractive intraocular lenses (IOLs)…
Study explores the true costs of treating pediatric cataracts
Analysis highlights discrepancies between adult, pediatric cataract procedures.
Stemming the Myopic Tide
Pediatric ophthalmologist Daniel Cyr discusses the findings of a recent study on rising global myopia levels
Evolution of DURYSTA® (bimatoprost intracameral implant) Coverage and Reimbursement
Webinar Description: The Eye Care Reimbursement Education Program is designed to provide information to assist members of the healthcare…
